SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations. SUNLENCA tablets are indicated for oral loading as a component of the initiation regimen for BIXL...
Prior to starting SUNLENCA for the treatment of HIV-1 in heavily treatment-experienced adults, healthcare providers should carefully select patients who agree to the required every 6 month injection dosing schedule and counsel patients about the importance of adherence to scheduled SUNLENCA dosing visits and concomitant oral antiretroviral therapy to help maintain viral suppression and reduce the risk of viral reb...
SUNLENCA tablets, 300 mg are beige, capsule-shaped, and film-coated with "GSI" debossed on one side and "62L" on the other side. SUNLENCA tablets are available in a bottle and blister packs, packaged as follows: Bottle SUNLENCA bottle contains 4 tablets (NDC 61958-3001-3). The bottle also contains a silica gel desiccant and polyester coil, and is closed with a child-resistant closure. Do not remove the desiccant p...
www.fda.gov/medwatch
www.SUNLENCA.comSUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations.
SUNLENCA tablets are indicated for oral loading as a component of the initiation regimen for BIXLENVO (bictegravir [BIC]/lenacapavir [LEN]), a complete regimen for treatment of HIV-1 infection, in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of BIXLENVO [see Dosage and Administration (2.3)].
Prior to starting SUNLENCA for the treatment of HIV-1 in heavily treatment-experienced adults, healthcare providers should carefully select patients who agree to the required every 6 month injection dosing schedule and counsel patients about the importance of adherence to scheduled SUNLENCA dosing visits and concomitant oral antiretroviral therapy to help maintain viral suppression and reduce the risk of viral rebound and potential development of resistance with missed doses [see Warnings and Precautions (5.2), Microbiology (12.4)].
SUNLENCA can be initiated using one of the two recommended dosage regimens in Table 1 and Table 2 below. Maintenance dosing is administered by subcutaneous injection every 6 months regardless of the initiation regimen. Healthcare providers should determine the appropriate initiation regimen for the patient. SUNLENCA oral tablets may be taken with or without food [see Clinical Pharmacology (12.3)].
| Treatment Time | |
|---|---|
| Dosage of SUNLENCA: Initiation | |
| Day 1 | 927 mg by subcutaneous injection (2 × 1.5 mL injections) and 600 mg orally (2 × 300 mg tablets) |
| Day 2 | 600 mg orally (2 × 300 mg tablets) |
| Dosage of SUNLENCA: Maintenance | |
| Every 6 months (26 weeks) * +/-2 weeks | 927 mg by subcutaneous injection (2 × 1.5 mL injections) |
* From the date of the last injection.
| Treatment Time | |
|---|---|
| Dosage of SUNLENCA: Initiation | |
| Day 1 | 600 mg orally (2 × 300 mg tablets) |
| Day 2 | 600 mg orally (2 × 300 mg tablets) |
| Day 8 | 300 mg orally (1 × 300 mg tablet) |
| Day 15 | 927 mg by subcutaneous injection (2 × 1.5 mL injections) |
| Dosage of SUNLENCA: Maintenance | |
| Every 6 months (26 weeks) * +/-2 weeks | 927 mg by subcutaneous injection (2 × 1.5 mL injections) |
* From the date of the last injection.
SUNLENCA tablets are used as a component of the initiation regimen for BIXLENVO. See BIXLENVO prescribing information.
The BIXLENVO dosing schedule in adults requires a two-day initiation regimen of BIXLENVO tablets plus SUNLENCA tablets taken orally, followed by a maintenance regimen of one tablet of BIXLENVO taken orally once daily (see Table 3). BIXLENVO must be taken with SUNLENCA tablets during the two-day initiation period. SUNLENCA is only indicated for the oral initiation of BIXLENVO treatment and is not to be used for the maintenance of BIXLENVO treatment. BIXLENVO and SUNLENCA tablets may be taken with or without food.
| Treatment Time | |
|---|---|
| Dosage: Initiation (BIXLENVO and SUNLENCA) | |
| Day 1 | BIXLENVO 75 mg/50 mg (1 tablet) orally *
and SUNLENCA 600 mg orally (2 × 300 mg tablets) |
| Day 2 | BIXLENVO 75 mg/50 mg (1 tablet) orally *
and SUNLENCA 600 mg orally (2 × 300 mg tablets) |
| Dosage: Maintenance (BIXLENVO only) | |
| Day 3 and thereafter | BIXLENVO 75 mg/50 mg (1 tablet) orally once daily* |
* See BIXLENVO prescribing information.
Treatment of HIV-1 in Heavily Treatment-Experienced Adults:
Planned Missed Injections
During the maintenance period, if a patient plans to miss a scheduled 6-month injection visit by more than 2 weeks, SUNLENCA tablets may be taken for up to 6 months until injections resume. Refer to Table 4 below for the recommended dosage after planned missed injections.
| Time since Last Injection | Recommendation |
|---|---|
| 26 to 28 weeks | Maintenance oral dosage of 300 mg taken once every 7 days for up to 6 months. Resume the maintenance injection dosage within 7 days after the last oral dose. |
Unplanned Missed Injections
Patients who miss a scheduled injection visit should be clinically reassessed, including consideration of lenacapavir resistance testing, to ensure resumption of therapy remains appropriate. During the maintenance period, if more than 28 weeks have elapsed since the last injection and SUNLENCA tablets have not been taken, see Table 5 below for the recommended dosage after unplanned missed injections. Adherence to the injection dosing schedule is strongly recommended [see Dosage and Administration (2.1) and Microbiology (12.4)].
| Time since Last Injection | Recommendation |
|---|---|
| More than 28 weeks | Reinitiate with Option 1 (Table 1) or Option 2 (Table 2) and then continue with maintenance injection dosing. |
Oral Loading for Initiation of BIXLENVO:
Missed Oral Initiation Dose
If the Day 1 or Day 2 oral initiation dose of SUNLENCA (600 mg; see Table 3) is missed, take it as soon as possible. Do not take SUNLENCA Day 1 and Day 2 oral initiation doses on the same day.
For BIXLENVO missed dose instructions, see BIXLENVO prescribing information.
SUNLENCA injection is only for subcutaneous administration into the abdomen by a healthcare provider. Do NOT administer intradermally due to risk of serious injection site reactions [see Warnings and Precautions (5.3)].
Use aseptic technique. Visually inspect the solution in the vials and prepared syringe for particulate matter and discoloration prior to administration. SUNLENCA injection is a yellow solution. Do not use SUNLENCA injection if the solution is discolored or if it contains particulate matter. Once the solution is withdrawn from the vials, the subcutaneous injections should be administered as soon as possible [see How Supplied/Storage and Handling (16)].
There are two SUNLENCA injection kits available [see How Supplied/Storage and Handling (16)]:
The Vial Access Device Injection Kit differs from the Withdrawal Needle Injection Kit only in how SUNLENCA injection is prepared (the components and associated method for withdrawal of the solution from the vials.
The Withdrawal Needle Injection Kit contains withdrawal needles that may be supplied with or without a safety shield. The presence or absence of a safety shield does not change how SUNLENCA injection is prepared.
Refer to the figures below for the relevant injection kit.
The injection kit components are for single use only. Two 1.5 mL injections are required for a complete dose.
Vial Access Device Injection Kit
Figure 1 identifies the components for use in the administration steps for the Vial Access Device Injection Kit, and the administration steps are provided in Figure 2. Use of a vial access device is required in this kit.
Figure 1 SUNLENCA Vial Access Device Injection Kit Components
Figure 2 SUNLENCA Injection Steps for Vial Access Device Injection Kit
Withdrawal Needle Injection Kit (withdrawal needle without safety shield)
Figure 3 identifies the components for use in the administration steps for the Withdrawal Needle Injection Kit (withdrawal needle supplied without a safety shield), and the administration steps are provided in Figure 4. The 18-gauge needle is for withdrawal only in this kit.
Figure 3 SUNLENCA Withdrawal Needle Injection Kit Components (withdrawal needle without safety shield)
Figure 4 SUNLENCA Injection Steps for Withdrawal Needle Injection Kit (withdrawal needle without safety shield)
Withdrawal Needle Injection Kit (withdrawal needle with safety shield)
Figure 5 identifies the components for use in the administration steps for the Withdrawal Needle Injection Kit (withdrawal needle supplied with a safety shield), and the administration steps are provided in Figure 6. The 18-gauge safety needle is for withdrawal only in this kit.
Figure 5 SUNLENCA Withdrawal Needle Injection Kit Components (withdrawal needle with safety shield)
Figure 6 SUNLENCA Injection Steps for Withdrawal Needle Injection Kit (withdrawal needle with safety shield)
SUNLENCA tablets: Each tablet contains 300 mg of lenacapavir. The tablets are beige, capsule-shaped, film-coated, and debossed with 'GSI' on one side of the tablet and '62L' on the other side of the tablet.
SUNLENCA injection: Each single-dose vial contains 463.5 mg/1.5 mL (309 mg/mL) of lenacapavir. The lenacapavir injectable solution is sterile, preservative-free, clear, and yellow with no visible particles.
Concomitant administration of SUNLENCA with strong CYP3A inducers is contraindicated due to decreased lenacapavir plasma concentrations, which may result in the loss of therapeutic effect and development of resistance to SUNLENCA [see Drug Interactions (7.1)].
Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections [such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia (PCP), or tuberculosis], which may necessitate further evaluation and treatment.
Autoimmune disorders (such as Graves' disease, polymyositis, Guillain-Barré syndrome, and autoimmune hepatitis) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable, and can occur many months after initiation of treatment.
Residual concentrations of lenacapavir may remain in the systemic circulation of patients for prolonged periods (up to 12 months or longer after the last subcutaneous dose). It is important to counsel patients that maintenance dosing by injection is required every 6 months, because missed doses or non-adherence to injections could lead to loss of virologic response and development of resistance [see Dosage and Administration (2.1)].
Lenacapavir, a moderate CYP3A inhibitor, may increase the exposure to, and therefore potential risk of adverse reactions from, drugs primarily metabolized by CYP3A initiated within 9 months after the last subcutaneous dose of SUNLENCA [see Drug Interactions and Clinical Pharmacology (7.2, 12.3)].
If SUNLENCA is discontinued, to minimize the potential risk of developing viral resistance, it is essential to initiate an alternative, fully suppressive antiretroviral regimen where possible no later than 28 weeks after the final injection of SUNLENCA. If virologic failure occurs during treatment, switch the patient to an alternative regimen if possible [see Dosage and Administration (2.1)].
Administration of SUNLENCA may result in local injection site reactions (ISRs). If clinically significant ISRs occur, evaluate and institute appropriate therapy and follow-up.
Manifestations of ISRs may include swelling, pain, erythema, nodule, induration, pruritus, extravasation or mass. Nodules and indurations at the injection site may take longer to resolve than other ISRs. In clinical studies, after a median follow-up of 553 days, 30% of nodules and 13% of indurations (in 10% and 1% of participants, respectively) associated with the first injections of SUNLENCA had not fully resolved. Measurements and qualitative assessments of ISRs were not routinely reported. Where described, the majority of the injection site nodules and indurations were palpable but not visible, and had a maximum size of approximately 1 to 4 cm [see Adverse Reactions (6.1)].
The mechanism driving the persistence of injection site nodules and indurations in some patients is not fully understood, but based on available data, they may be related to the presence of the subcutaneous drug depot. In some patients who had a skin biopsy performed of an injection site nodule or induration, dermatopathology revealed foreign body inflammation or granulomatous response.
Improper administration (intradermal injection) has been associated with serious injection site reactions, including necrosis and ulcer [see Adverse Reactions (6)]. Ensure SUNLENCA is only administered subcutaneously in the abdomen [see Dosage and Administration (2.5)].
The following adverse reactions are discussed in other sections of the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Treatment of HIV-1 in Heavily Treatment-Experienced Adults
The primary safety assessment of SUNLENCA was based on data from heavily treatment-experienced adult participants with HIV who received SUNLENCA in a Phase 2/3 trial (CAPELLA; N=72) through Week 52 (median duration on study of 71 weeks) [see Clinical Studies (14.1)], as well as supportive data in treatment-naïve adult participants with HIV who received SUNLENCA in a Phase 2 trial (CALIBRATE; N=157) through Week 54 (median duration of exposure of 66 weeks).
The most common adverse reactions (all Grades) reported in at least 3% of participants in CAPELLA were nausea and injection site reactions. The proportion of participants in CAPELLA who discontinued treatment with SUNLENCA due to adverse events, regardless of severity, was 1% (Grade 1 injection site nodule in 1 participant). Table 6 displays the frequency of adverse reactions (all Grades) greater than or equal to 3% in the SUNLENCA group.
| Adverse Reactions | SUNLENCA + Background Regimen (N=72) |
|---|---|
| Injection Site Reactions | 65% |
| Nausea | 4% |
* Frequencies of adverse reactions are based on all adverse events attributed to trial drug by the investigator, based on all participants (cohorts 1 and 2) in CAPELLA.
The majority (96%) of all adverse reactions associated with SUNLENCA were mild or moderate in severity.
Injection-Associated Adverse Reactions
Local Injection Site Reactions (ISRs):
The most frequent adverse reactions were ISRs. Of the 72 participants in CAPELLA, 65% had experienced an ISR attributed to study drug through at least the Week 52 visit. Most participants had mild (Grade 1, 44%) or moderate (Grade 2, 17%) ISRs. Four percent of participants experienced a severe (Grade 3) ISR (erythema, pain, swelling) that resolved within 15 days. The ISRs reported in more than 1% of participants were swelling (36%), pain (31%), erythema (31%), nodule (25%), induration (15%), pruritus (6%), extravasation (3%) and mass (3%). ISRs reported in 1% of participants included discomfort, hematoma, edema, and ulcer.
Nodules and indurations at the injection site took longer to resolve than other ISRs. The median time to resolution of all ISRs, excluding nodules and indurations, was 5 days (range: 1 to 183). The median time to resolution of nodules and indurations associated with the first injections of SUNLENCA was 148 (range: 41 to 727) and 70 (range: 3 to 252) days, respectively. After a median follow up of 553 days, 30% of nodules and 13% of indurations (in 10% and 1% of participants, respectively) associated with the first injections of SUNLENCA had not fully resolved. Qualitative descriptions of injection site nodules and indurations were not routinely reported, but, where reported, the majority of injection site nodules and indurations were palpable but not visible. Measurements of injection site nodules and indurations were not routinely performed or standardized, but where measurements were reported, the maximum size for the majority of injection site nodules and indurations was approximately 1 to 4 cm [see Warnings and Precautions (5.3)].
Laboratory Abnormalities
The frequency of laboratory abnormalities (Grades 3 to 4) occurring in at least 2% of participants in CAPELLA are presented in Table 7. A causal association between SUNLENCA and these laboratory abnormalities has not been established.
| Laboratory Parameter Abnormality | SUNLENCA + Background Regimen (N=72) * |
|---|---|
| ALT= alanine aminotransferase; AST= aspartate aminotransferase; ULN = upper limit of normal | |
| Creatinine ( >1.8 × ULN or ≥1.5 × baseline) | 13% |
| Glycosuria (>2+) † | 6% |
| Hyperglycemia (fasting) (>250 mg/dL) | 5% |
| Proteinuria (>2+) † | 4% |
| ALT (≥5 × ULN) † | 3% |
| AST (≥5 × ULN) | 3% |
| Direct Bilirubin (>ULN) † | 3% |
* Frequencies are based on treatment-emergent laboratory abnormalities in all participants (cohorts 1 and 2) in CAPELLA. Percentages were calculated based on the number of participants with post-baseline toxicity grades for each laboratory parameter (n=72 for all parameters except hyperglycemia fasting n=57).
† Grade 3 only (no Grade 4 values reported).
In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during postmarketing use. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
General disorders and administration site conditions
Injection site necrosis [see Warnings and Precautions (5.3)].
Lenacapavir is a substrate of P-gp, UGT1A1, and CYP3A.
Strong or Moderate CYP3A Inducers
Drugs that are strong or moderate inducers of CYP3A may significantly decrease plasma concentrations of lenacapavir [see Clinical Pharmacology (12.3)], which may result in loss of therapeutic effect of SUNLENCA and development of resistance. Concomitant administration of SUNLENCA with strong CYP3A inducers during SUNLENCA treatment is contraindicated [see Contraindications (4)]. Concomitant administration of SUNLENCA with moderate CYP3A inducers during SUNLENCA treatment is not recommended.
Combined P-gp, UGT1A1, and Strong CYP3A Inhibitors
Combined P-gp, UGT1A1, and strong CYP3A inhibitors may significantly increase plasma concentrations of SUNLENCA. Concomitant administration of SUNLENCA with these inhibitors is not recommended.
Lenacapavir is a moderate inhibitor of CYP3A. Due to the long half-life of lenacapavir following subcutaneous administration, SUNLENCA may increase the exposure of drugs primarily metabolized by CYP3A [see Clinical Pharmacology (12.3)] initiated within 9 months after the last subcutaneous dose of SUNLENCA, which may increase the potential risk of adverse reactions. See the prescribing information of the sensitive CYP3A substrate for dosing recommendations with moderate inhibitors of CYP3A.
Table 8 provides a listing of clinically significant drug interactions with recommended prevention or management strategies, but is not all inclusive. The drug interactions described are based on studies conducted with SUNLENCA or are drug interactions that may occur with SUNLENCA [see Contraindications (4) and Clinical Pharmacology (12.3)].
| Concomitant Drug Class: Drug Name | Effect on Concentration * | Clinical Comment |
|---|---|---|
| Antiarrhythmics: digoxin | ↑ digoxin | Use with caution and monitor digoxin therapeutic concentration. |
| Anticoagulants: Direct Oral Anticoagulants (DOACs) rivaroxaban dabigatran edoxaban | ↑ DOAC | Refer to the DOAC prescribing information for concomitant administration with moderate CYP3A inhibitors and/or P-gp inhibitors. |
| Anticonvulsants: carbamazepine oxcarbazepine phenobarbital phenytoin | ↓ lenacapavir | Concomitant administration of carbamazepine, oxcarbazepine, phenobarbital, or phenytoin may result in loss of therapeutic effect and development of resistance. Concomitant administration of SUNLENCA with carbamazepine or phenytoin is contraindicated. Concomitant administration of SUNLENCA with oxcarbazepine or phenobarbital is not recommended. Consider use of alternative anticonvulsants. |
| Antiretroviral Agents: atazanavir/cobicistat † atazanavir/ritonavir | ↑ lenacapavir (atazanavir/cobicistat, atazanavir/ritonavir) | Concomitant administration of efavirenz, nevirapine, or tipranavir/ritonavir may result in loss of therapeutic effect and development of resistance. |
| efavirenz †
nevirapine tipranavir/ritonavir | ↓ lenacapavir (efavirenz, nevirapine, tipranavir/ritonavir) | Concomitant administration with atazanavir/cobicistat, atazanavir/ritonavir, efavirenz, nevirapine, or tipranavir/ritonavir is not recommended. |
| Antimycobacterials: rifabutin rifampin † rifapentine | ↓ lenacapavir | Concomitant administration of rifabutin, rifampin and rifapentine may result in loss of therapeutic effect and development of resistance. Concomitant administration of SUNLENCA with rifampin is contraindicated [see Contraindications (4)]. Concomitant administration of SUNLENCA with rifabutin or rifapentine is not recommended. |
| Corticosteroids (systemic): cortisone/hydrocortisone dexamethasone | ↑ corticosteroids (systemic) | Concomitant administration with systemic corticosteroids whose exposures are significantly increased by CYP3A inhibitors can increase the risk for Cushing's syndrome and adrenal suppression. Initiate with the lowest starting dose and titrate carefully while monitoring for safety. |
| ↓ lenacapavir (dexamethasone) | Concomitant administration of systemic dexamethasone may result in loss of therapeutic effect of lenacapavir and development of resistance. Alternative corticosteroids to dexamethasone should be considered, particularly for long-term use. | |
| Ergot derivatives: dihydroergotamine ergotamine methylergonovine | ↑ dihydroergotamine ↑ ergotamine ↑ methylergonovine | Concomitant administration of SUNLENCA with dihydroergotamine, ergotamine or methylergonovine is not recommended. |
| Herbal Products: St. John's wort ‡ (Hypericum perforatum) | ↓ lenacapavir | Concomitant administration of St. John's wort may result in loss of therapeutic effect and development of resistance. Concomitant administration of SUNLENCA with St. John's wort is contraindicated. |
| HMG-CoA Reductase Inhibitors: lovastatin simvastatin | ↑ lovastatin ↑ simvastatin | Initiate lovastatin and simvastatin with the lowest starting dose and titrate carefully while monitoring for safety (e.g., myopathy). |
| Narcotic analgesics metabolized by CYP3A: e.g., fentanyl, oxycodone | ↑ fentanyl ↑ oxycodone | Careful monitoring of therapeutic effects and adverse reactions associated with CYP3A-metabolized narcotic analgesics (including potentially fatal respiratory depression) is recommended with co-administration. |
| tramadol | ↑ tramadol | A decrease in dose may be needed for tramadol with concomitant use. |
| Narcotic analgesic for treatment of opioid dependence: buprenorphine, methadone | buprenorphine: effects unknown methadone: effects unknown | Initiation of buprenorphine or methadone in patients taking SUNLENCA: Carefully titrate the dose of buprenorphine or methadone to the desired effect; use the lowest feasible initial or maintenance dose. Initiation of SUNLENCA in patients taking buprenorphine or methadone: A dose adjustment for buprenorphine or methadone may be needed. Monitor clinical signs and symptoms. |
| Opioid Antagonist: naloxegol | ↑ naloxegol | Avoid use with SUNLENCA; if unavoidable, decrease the dosage of naloxegol and monitor for adverse reactions. |
| Phosphodiesterase-5 (PDE-5) Inhibitors: sildenafil tadalafil vardenafil | ↑ PDE-5 inhibitors | Use of PDE-5 inhibitors for pulmonary arterial hypertension (PAH): Concomitant administration of SUNLENCA with tadalafil for the treatment of PAH is not recommended. Use of PDE-5 inhibitors for erectile dysfunction (ED): Refer to the prescribing information of PDE-5 inhibitors for dose recommendations. |
| Sedatives/Hypnotics: midazolam (oral) † triazolam | ↑ midazolam (oral) ↑ triazolam | Use with caution when midazolam or triazolam is concomitantly administered with SUNLENCA |
Based on drug interaction studies conducted with SUNLENCA, no clinically significant drug interactions have been observed with: darunavir/cobicistat, cobicistat, famotidine, pitavastatin, rosuvastatin, tenofovir alafenamide, and voriconazole.
Pregnancy Exposure Registry
There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to SUNLENCA during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263.
Risk Summary
Available data from a randomized, controlled trial with lenacapavir use during pregnancy in individuals without HIV-1 have not identified a drug-associated risk for miscarriage, or adverse maternal or fetal outcomes when compared to an active control (see Data). The rate of major birth defects in lenacapavir-exposed pregnancies did not exceed the background prevalence rates. The risk estimates are imprecise due to small numbers of exposed pregnancies (see Data). In animal reproduction studies, no adverse developmental effects were observed when lenacapavir was administered to rats and rabbits at exposures (AUC) ≥16 times the exposure in humans at the recommended human dose (RHD) of SUNLENCA (see Data).
The background risk of major birth defects and miscarriage for the indicated population is unknown. The background rate of major birth defects in a U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP) is 2.7%. The rate of miscarriage is not reported in the APR. The estimated background rate of miscarriage in clinically recognized pregnancies in the U.S. general population is 15 to 20%.
Data
Human Data
In a randomized, controlled trial of individuals without HIV-1 in Uganda and South Africa, there were 208 pregnancies exposed to lenacapavir with known outcomes and 132 deliveries (both live and non-live). In the active control arm of this trial, there were 109 pregnancies with known outcomes and 61 deliveries (both live and non-live). The adverse pregnancy outcomes of spontaneous abortion, stillbirth, preterm birth, and small for gestational age were similar across both treatment groups.
There were two major birth defects in the lenacapavir arm. Both were ventricular septal defects. This resulted in a rate of major birth defects that fell within the background prevalence rate for major birth defects.
Concentrations of lenacapavir during each trimester of pregnancy and postpartum were comparable to those in non-pregnant participants.
Animal Data
Lenacapavir was administered intravenously to pregnant rabbits (up to 20 mg/kg/day on gestation days (GD) 7 to 19), orally to rats (up to 300 mg/kg/day on GD 6 to 17), and subcutaneously to rats (up to 300 mg/kg on GD 6). No significant toxicological effects on embryo-fetal (rats and rabbits) or pre/postnatal (rats) development were observed at exposures (AUC) approximately 16 times (rats) and 39 times (rabbits) the exposure in humans at the RHD of SUNLENCA.
Risk Summary
Lenacapavir is present in human milk. Lenacapavir was detected at very low levels in infants who were breastfed by individuals who became pregnant while receiving lenacapavir (see Data). No adverse effects of lenacapavir in breastfed infants have been observed. It is not known if lenacapavir affects milk production.
Potential risks of breastfeeding include: (1) HIV-1 transmission (in infants without HIV-1), (2) developing viral resistance (in infants with HIV-1), and (3) adverse reactions in a breastfed infant similar to those seen in adults.
Data
Human data
The median lenacapavir concentration in human breast milk to maternal plasma ratio in participants (n=8) who received lenacapavir was 0.63 (range: 0.29 to 1.90). The median infant-to-mother plasma ratio for lenacapavir in infants (n=10) who were breastfed by individuals receiving lenacapavir from 0 to less than 13 weeks after delivery was 0.06 (range: 0.01 to 0.20).
The safety and effectiveness of SUNLENCA have not been established in pediatric patients.
Clinical studies of SUNLENCA did not include sufficient numbers of participants aged 65 and over to determine whether they respond differently from younger patients.
No dosage adjustment of SUNLENCA is recommended in patients with mild, moderate or severe renal impairment (estimated creatinine clearance greater than or equal to 15 mL per minute). SUNLENCA has not been studied in patients with ESRD (estimated creatinine clearance less than 15 mL per minute) [see Clinical Pharmacology (12.3)].
No dosage adjustment of SUNLENCA is recommended in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. SUNLENCA has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) [see Clinical Pharmacology (12.3)].
No data are available on overdose of SUNLENCA in patients. If overdose occurs, monitor the patient for evidence of toxicity. Treatment of overdose with SUNLENCA consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient. As lenacapavir is highly bound to plasma proteins, it is unlikely to be significantly removed by dialysis.
SUNLENCA tablets and SUNLENCA injection contain lenacapavir sodium, a capsid inhibitor.
The chemical name of lenacapavir sodium is: Sodium (4-chloro-7-(2-((S)-1-(2-((3bS,4aR)-5,5-difluoro-3-(trifluoromethyl)-3b,4,4a,5-tetrahydro-1H-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol-1-yl)acetamido)-2-(3,5-difluorophenyl)ethyl)-6-(3-methyl-3-(methylsulfonyl)but-1-yn-1-yl)pyridin-3-yl)-1-(2,2,2-trifluoroethyl)-1H-indazol-3-yl)(methylsulfonyl)amide.
Lenacapavir sodium has a molecular formula of C39H31ClF10N7NaO5S2, a molecular weight of 990.3, and the following structural formula:
Lenacapavir sodium is a light yellow to yellow solid and is practically insoluble in water.
SUNLENCA tablets are for oral administration. Each film-coated tablet contains 300 mg of lenacapavir (present as 306.8 mg lenacapavir sodium) and the following inactive ingredients: copovidone, croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, and poloxamer 407. The tablets are film-coated with a coating material containing iron oxide black, iron oxide red, iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.
SUNLENCA injection is for subcutaneous administration. Each single-dose vial contains 463.5 mg/1.5 mL (309 mg/mL) of lenacapavir (present as 473.1 mg/1.5 mL of lenacapavir sodium) as a sterile, preservative-free, clear, yellow solution and the following inactive ingredients: 896.3 mg of polyethylene glycol 300 (as solvent) and water for injection. The apparent pH range of the injection is 9.0–10.2.
The vial stoppers are not made with natural rubber latex.
SUNLENCA is an HIV-1 antiretroviral agent [see Microbiology (12.4)].
Exposure-Response
In CAPELLA, oral loading doses (600 mg on Day 1 and Day 2, 300 mg on Day 8) followed by subcutaneous doses (927 mg every 6 months starting on Day 15) of SUNLENCA in heavily treatment-experienced participants with multiclass resistant HIV-1, efficacy outcomes (change in plasma HIV-1 RNA from Day 1 to Day 14, and percentage of participants with HIV-1 RNA less than 50 copies/mL at Week 26) were similar across the range of observed lenacapavir exposures.
Cardiac Electrophysiology
At supratherapeutic exposures of lenacapavir (9-fold higher than the therapeutic exposures of SUNLENCA), SUNLENCA does not prolong the QTcF interval to any clinically relevant extent.
The pharmacokinetic (PK) properties of lenacapavir are provided in Table 9. The PK parameter estimates of SUNLENCA after oral and subcutaneous administration in heavily-treatment experienced participants with HIV-1 are provided in Table 10. The estimated lenacapavir exposures are comparable between the two recommended dosing regimens.
| Oral | Subcutaneous | ||
|---|---|---|---|
| Absorption | |||
| % Absolute bioavailability | 6 to 10 | 100 * | |
| Tmax † | 4 hours | 77 to 84 days ‡ | |
| Effect of Food | |||
| Effect of low-fat meal (relative to fasting) § | AUCinf ratio | 98.6 (58.2,167.2) | - |
| Cmax ratio | 115.8 (55.4, 242.1) | - | |
| Effect of high-fat meal (relative to fasting) ¶ | AUCinf ratio | 115.2 (72.0, 184.5) | - |
| Cmax ratio | 145.2 (77.9, 270.5) | - | |
| Distribution | |||
| Apparent volume of distribution (Vd/F, L) | 19240 | 9500 to 11700 | |
| % bound to human plasma proteins | >98.5 | ||
| Blood-to-plasma ratio | 0.5 to 0.7 # | ||
| Elimination | |||
| t1/2 | 10 to 12 days | 8 to 12 weeks | |
| Clearance (mean apparent clearance, L/h) | 55 | 4.2 | |
| % of dose of unchanged drug in plasma ♠ | 69 | ||
| Metabolism | |||
| Metabolic pathway(s) | CYP3A (minor) UGT1A1 (minor) | ||
| Excretion | |||
| Major routes of elimination | Excretion of unchanged drug into feces ♥ | ||
| % of dose excreted in urine ♠ | <1 | ||
| % of dose excreted in feces (% unchanged) ♥ | 76 (33) | ||
* Values reflect absolute bioavailability following subcutaneous administration of the 927 mg dose.
† Values reflect administration of lenacapavir with or without food.
‡ Due to slow release from the site of subcutaneous administration, the absorption profile of subcutaneously administered lenacapavir is complex.
§ Values refer to geometric mean ratio [low-fat meal/fasting] in PK parameters and (90% confidence interval). Low fat meal is approximately 400 kcal, 25% fat.
¶ Values refer to geometric mean ratio [high-fat meal/fasting] in PK parameters and (90% confidence interval). High fat meal is approximately 1000 kcal, 50% fat.
# Values reflect the blood-to-plasma ratio of lenacapavir following a single dose intravenous administration of [14C] lenacapavir through 336 hours postdose.
♠ Dosing in mass balance studies: single dose intravenous administration of [14C] lenacapavir to participants without HIV-1.
♥ Metabolized via oxidation, N-dealkylation, hydrogenation, amide hydrolysis, glucuronidation, hexose conjugation, pentose conjugation, and glutathione conjugation; primarily via CYP3A and UGT1A1 and no single circulating metabolite accounted for >10% of plasma drug-related exposure.
| Parameter Mean (%CV) | Recommended Dosing Regimen, Option 1 * | Recommended Dosing Regimen, Option 2 * | |
|---|---|---|---|
| Day 1: 600 mg (oral) + 927 mg (SC) Day 2: 600 mg (oral) | Days 1 and 2: 600 mg (oral), Day 8: 300 mg (oral), Day 15: 927 mg (SC) | ||
| Day 1 to end of Month 6 | Days 1 to 15 | Day 15 to end of Month 6 | |
| CV = coefficient of variation; NA = not applicable; SC = subcutaneous | |||
| Cmax
(ng/mL) | 101.4 (53.1) | 88.0 (72.4) | 86.5 (51.7) |
| AUCtau
(h∙ng/mL) | 242266 (46.0) | 19496 (72.6) | 239163 (47.2) |
| Ctrough
(ng/mL) | 32.5 (57.2) | 46.9 (72.3) | 32.5 (57.5) |
* Predicted exposures utilizing population PK analysis.
Lenacapavir exposures after subcutaneous administration were similar between heavily treatment experienced participants with HIV-1 and participants without HIV-1 based on population pharmacokinetics analysis. Lenacapavir exposures (AUCtau, Cmax and Ctrough) after oral administration were 28% to 43% higher in participants with HIV-1 who were heavily treatment experienced, compared to participants without HIV-1 based on population PK analysis. These differences were not considered clinically relevant.
For PK parameter estimates of SUNLENCA tablets following oral administration as part of the BIXLENVO initiation regimen, see BIXLENVO prescribing information.
Specific Populations
There were no clinically significant differences in the pharmacokinetics of lenacapavir based on age (18 to 78 years), sex, ethnicity (hispanic or non-hispanic), race (white, black, asian or other), body weight (41.4 to 164 kg), severe renal impairment (creatinine clearance of 15 to less than 30 mL per minute, estimated by Cockroft-Gault method), or moderate hepatic impairment (Child-Pugh Class B). The effect of end-stage renal disease (including dialysis), or severe hepatic impairment (Child-Pugh Class C), on the pharmacokinetics of lenacapavir is unknown. As lenacapavir is greater than 98.5% protein bound, dialysis is not expected to alter exposures of lenacapavir [see Use in Specific Populations (8.6)].
Pregnancy
There were no clinically relevant changes in lenacapavir exposure during pregnancy and postpartum.
Drug Interaction Studies
Clinical Studies
Clinical drug-drug interaction study indicated that lenacapavir is a substrate of CYP3A, P-gp, and UGT1A1. Table 11 summarizes the pharmacokinetic effects of other drugs on lenacapavir.
Lenacapavir is a moderate inhibitor of CYP3A. Lenacapavir is an inhibitor of P-gp and BCRP but does not inhibit OATP. Table 12 summarizes the pharmacokinetic effects of lenacapavir on other drugs.
| Coadministered Drug | Dose of Coadministered Drug (mg) | Mean Ratio of Lenacapavir Pharmacokinetic Parameters (90% CI); No effect = 1.00 | |
|---|---|---|---|
| Cmax | AUC | ||
| Cobicistat (fed) (Inhibitor of CYP3A [strong] and P-gp) | 150 once daily | 2.10 (1.62, 2.72) | 2.28 (1.75, 2.96) |
| Darunavir / cobicistat (fed) (Inhibitor of CYP3A [strong] and inhibitor and inducer of P-gp) | 800/150 once daily | 2.30 (1.79, 2.95) | 1.94 (1.50, 2.52) |
| Voriconazole (fasted) (Inhibitor of CYP3A [strong]) | 400 twice daily, 200 twice daily ‡ | 1.09 (0.81, 1.47) | 1.41 (1.10, 1.81) |
| Atazanavir / cobicistat (fed) (Inhibitor of CYP3A [strong] and UGT1A1 and P-gp) | 300/150 once daily | 6.60 (4.99, 8.73) | 4.21 (3.19, 5.57) |
| Rifampin (fasted) (Inducer of CYP3A [strong] and P-gp and UGT) | 600 once daily | 0.45 (0.34, 0.60) | 0.16 (0.12, 0.20) |
| Efavirenz (fasted) (Inducer of CYP3A [moderate] and P-gp) | 600 once daily | 0.64 (0.45, 0.92) | 0.44 (0.32, 0.59) |
| Famotidine (2 hours before, fasted) | 40 once daily | 1.01 (0.75, 1.34) | 1.28 (1.00, 1.63) |
* Single dose of lenacapavir 300 mg administered orally.
† All interaction studies conducted in participants without HIV-1.
‡ 400 mg loading dose twice daily for a day, followed by 200 mg maintenance dose twice daily.
| Coadministered Drug | Dose of Coadministered Drug (mg) | Mean Ratio of Coadministered Drug Pharmacokinetic Parameters (90% CI) ‡; No effect = 1.00 | |
|---|---|---|---|
| Cmax | AUC | ||
| Tenofovir alafenamide (fed) (substrate of P-gp) | 25 single dose | 1.24 (0.98, 1.58) | 1.32 (1.09, 1.59) |
| Tenofovir §
(substrate of P-gp) | 1.23 (1.05, 1.44) | 1.47 (1.27, 1.71) | |
| Pitavastatin (simultaneous administration, fed) (substrate of OATP) | 2 single dose | 1.00 (0.84, 1.19) | 1.11 (1.00, 1.25) |
| Pitavastatin (3 days after lenacapavir, fed) (substrate of OATP) | 2 single dose | 0.85 (0.69, 1.05) | 0.96 (0.87, 1.07) |
| Rosuvastatin (fed) (substrate of BCRP and OATP) | 5 single dose | 1.57 (1.38, 1.80) | 1.31 (1.19, 1.43) |
| Midazolam (simultaneous administration, fed) (substrate of CYP3A) | 2.5 single dose | 1.94 (1.81, 2.08) | 3.59 (3.30, 3.91) |
| 1-hydroxymidazolam ¶
(substrate of CYP3A) | 0.54 (0.50, 0.59) | 0.76 (0.72, 0.80) | |
| Midazolam (1 day after lenacapavir, fed) (substrate of CYP3A) | 2.5 single dose | 2.16 (2.02, 2.30) | 4.08 (3.77, 4.41) |
| 1-hydroxymidazolam ¶
(substrate of CYP3A) | 0.52 (0.48, 0.57) | 0.84 (0.80, 0.88) | |
* All interaction studies conducted in participants without HIV-1.
† Following 600 mg twice daily for 2 days, single 600 mg doses of lenacapavir were administered with each coadministered drug, resulting in lenacapavir exposures similar to or higher than those at the recommended dosage regimen.
‡ All No Effect Boundaries are 70% to 143%.
§ Tenofovir alafenamide is converted to tenofovir in vivo.
¶ Major active metabolite of midazolam.
In Vitro Studies
Cytochrome P450 (CYP) Enzymes: Lenacapavir is not a substrate, inducer, or inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. Lenacapavir is not an inducer of CYP3A4.
Uridine diphosphate (UDP)-glucuronosyl transferase (UGT) Enzymes: Lenacapavir is not an inhibitor of UGT1A1.
Transporter Systems: Lenacapavir is not an inhibitor of organic anion transporter 1 (OAT1), OAT3, organic cation transporter (OCT)1, OCT2, multidrug and toxin extrusion transporter (MATE) 1, or MATE 2-K. Lenacapavir is not a substrate of BCRP, OATP1B1, or OATP1B3.
Mechanism of Action
Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (p24) subunits in hexamers. Surface plasmon resonance sensorgrams showed dose-dependent and saturable binding of lenacapavir to cross-linked wild-type capsid hexamer with an equilibrium binding constant (KD) of 1.4 nM. Lenacapavir inhibits HIV-1 replication by interfering with multiple essential steps of the viral lifecycle, including capsid-mediated nuclear uptake of HIV-1 proviral DNA (by blocking nuclear import proteins binding to capsid), virus assembly and release (by interfering with Gag/Gag-Pol functioning, reducing production of capsid protein subunits), and capsid core formation (by disrupting the rate of capsid subunit association, leading to malformed capsids).
Antiviral Activity in Cell Culture
Lenacapavir has antiviral activity that is specific to human immunodeficiency virus (HIV-1 and HIV-2). The antiviral activity of lenacapavir against laboratory and clinical isolates of HIV-1 was assessed in T-lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells, and CD4+ T-lymphocytes with EC50 values ranging from 30 to 190 pM. Lenacapavir displayed antiviral activity in cell culture against all HIV-1 groups (M, N, O), including subtypes A, A1, AE, AG, B, BF, C, D, E, F, F1, G, H with EC50 values ranging from 20 and 160 pM. The median EC50 value for subtype B isolates (n=8) was 40 pM. Lenacapavir was 15- to 25-fold less active against HIV-2 isolates relative to HIV-1.
In a study of lenacapavir in combination with representatives from the major classes of anti-retroviral agents (INSTIs, NNRTIs, NRTIs, and PIs), no antagonism of antiviral activity was observed.
Resistance
In Cell Culture
HIV-1 variants with reduced susceptibility to lenacapavir have been selected in cell culture. Resistance selections with lenacapavir identified 7 substitutions in capsid: L56I, M66I, Q67H, K70N, N74D/S, and T107N singly or in dual combination that conferred 4- to >3,226-fold reduced phenotypic susceptibility to lenacapavir relative to wild-type (WT) virus. The M66I substitution alone or in combination conferred >3,226-fold decreased susceptibility to lenacapavir in a single-cycle infectivity assay; substitutions Q67H and T107N, conferred 4- to 6.3-fold decreased susceptibility; K70N, N74D and Q67H/N74S conferred 22- to 32-fold decreased susceptibility; and L56I conferred 239-fold decreased susceptibility.
In Clinical Trials
In CAPELLA, 39% (28/72) of heavily treatment-experienced participants met the criteria for resistance analyses through Week 156 (HIV-1 RNA ≥ 50 copies/mL at confirmed virologic failure [suboptimal virologic response at Week 4, virologic rebound, or viremia at last visit]) and were analyzed for lenacapavir resistance-associated substitution emergence. Lenacapavir resistance-associated capsid substitutions were found in 57% (n=16) of participants with confirmed virologic failure who had post-baseline capsid genotypic resistance data (n=28).
In the 16 participants with LEN resistance emergence through Week 156, 6 participants had emergence of the M66I substitution along with other substitutions (Q67H/K/N, K70N/R/S, N74D, A105T, T107A/C/S), 4 participants had emergence of Q67H + K70R with or without substitutions A105T and/or T107N or S, 2 participants had emergence of T107A or S alone, 1 participant had emergence of Q67K + K70H, 1 participant had emergence of K70N + N74K + T107T/N, 1 participant had emergence of Q67H alone, and 1 participant had emergence of N74D alone.
Phenotypic analyses of the confirmed virologic failure isolates with emergent lenacapavir resistance-associated substitutions showed 4.5- to >1428-fold decreases in lenacapavir susceptibility when compared to WT.
Among the 16 participants with virologic failure who developed lenacapavir resistance-associated substitutions in capsid, 6 received SUNLENCA in combination with a background regimen with no fully active antiretrovirals based on the baseline genotypic and/or phenotypic resistance. Therefore, given the risk of developing resistance in situations of functional monotherapy, careful consideration should be given to having fully active drugs in addition to SUNLENCA in the treatment regimen.
Nine participants with virologic failure had emergent resistance substitutions to components of the optimized background regimen (OBR) including NNRTI substitutions K103N/S and V106M, NRTI substitutions L74I, M184I/V, K65K/R, and K65R and S68N from mixtures at baseline, and emergent protease resistance substitutions M46I, I47I/V, I54I/L, V82V/A, I84I/V, L90L/M.
Oral Maintenance for Missed Injections
Of the 57 participants who received oral maintenance, 1 participant in Cohort 2 met the criteria for resistance analysis. The participant had emergence of lenacapavir resistance substitution N74D in capsid with no phenotypic data due to assay failure.
Lenacapavir Resistance with Suboptimal Adherence to Other Antiretroviral Drugs in the Regimen
The development of lenacapavir-associated capsid resistance substitutions can occur with suboptimal adherence to the other oral antivirals in the regimen. Seven of the 16 participants who had virologic rebound and developed lenacapavir resistance substitutions achieved resuppresion to HIV-1 RNA < 50 copies/mL on background oral regimens that included darunavir and/or dolutegravir. With lenacapavir resistance substitutions and decreased susceptibility to lenacapavir, it is unclear how much antiviral activity lenacapavir is contributing to the resuppression of HIV-1 RNA in these participants. Three of the 16 participants had a subsequent viral load rebound associated with additional emergent lenacapavir resistance substitutions and higher fold changes to lenacapavir. This supports that there was reduced lenacapavir antiviral activity from the previous emergent lenacapavir resistance substitutions, which contributed to further lenacapavir resistance emergence. Additionally, in these 3 participants, there was no evidence of emergent resistance to the oral OBR, signifying suboptimal adherence to the oral OBR and functional lenacapavir monotherapy.
Thus, adherence to other antiretroviral drugs in the regimen should be optimized while the patient is receiving SUNLENCA. During SUNLENCA treatment, if suboptimal adherence to the oral antiretroviral regimen occurs with concurrent HIV-1 RNA viral load increases (i.e., virologic failure), lenacapavir resistance should be assessed, and if detected, consideration should be given to discontinuing SUNLENCA treatment [see Dosage and Administration (2.1), Warnings and Precautions (5.2)].
Cross-Resistance
The antiviral activity in cell culture of lenacapavir was determined against a broad spectrum of HIV-1 site-directed mutants and patient-derived HIV-1 isolates with resistance to the four main classes of anti-retroviral agents (INSTI, NNRTI, NRTI, and PI; n=58), as well as to viruses resistant to the gp120-directed attachment inhibitor fostemsavir, the CD4+-directed post-attachment inhibitor ibalizumab, the CCR5 co-receptor antagonist maraviroc, and the gp41 fusion inhibitor enfuvirtide (n=42). These data indicated that lenacapavir remained fully active against all variants tested, thereby demonstrating a non-overlapping resistance profile. In addition, the antiviral activity of lenacapavir in patient isolates was unaffected by the presence of naturally occurring Gag polymorphisms and substitutions at protease cleavage sites.
Carcinogenesis
Lenacapavir was not carcinogenic in a 6-month rasH2 transgenic mouse study in males or females at doses of up to 300 mg/kg/dose once every 13 weeks.
A 104-week carcinogenicity study was conducted in male and female rats at lenacapavir doses of 0, 102, 309, or 927 mg/kg by subcutaneous injection once every 13-weeks. A treatment-related increase in the incidence of malignant sarcoma at the injection site was observed in males and a treatment-related increase in combined benign fibroma and malignant fibrosarcoma at the injection site was observed in females, at the highest dose (927 mg/kg). This dose in rats resulted in an exposure approximately 34-times the human exposure at the RHD, based on AUC. These tumors are considered to be a secondary response to chronic tissue irritation and granulomatous inflammation, due to the depot effect of lenacapavir following subcutaneous injection. The clinical relevance of these findings are unknown.
Mutagenesis
Lenacapavir was not mutagenic in a battery of in vitro and in vivo genotoxicity assays, including microbial mutagenesis, chromosome aberration in human peripheral blood lymphocytes, and in in vivo rat micronucleus assays.
Impairment of Fertility
There were no effects on fertility, mating performance or early embryonic development when lenacapavir was administered to rats at systemic exposures (AUC) 5 times the exposure to humans at the RHD of SUNLENCA.
The efficacy and safety of SUNLENCA in heavily treatment-experienced participants with multidrug resistant HIV-1 is based on 52-week data from CAPELLA, a randomized, placebo-controlled, double-blind, multicenter trial (NCT 04150068).
CAPELLA was conducted in 72 heavily treatment-experienced participants with multiclass resistant HIV-1. Participants were required to have a viral load ≥ 400 copies/mL, documented resistance to at least two antiretroviral medications from each of at least 3 of the 4 classes of antiretroviral medications (NRTI, NNRTI, PI and INSTI), and ≤ 2 fully active antiretroviral medications from the 4 classes of antiretroviral medications remaining at baseline due to resistance, intolerability, drug access, contraindication, or other safety concerns.
The trial was composed of two cohorts. Participants were enrolled into the randomized cohort (cohort 1, N=36) if they had a < 0.5 log10 HIV-1 RNA decline compared to the screening visit. Participants were enrolled into the non-randomized cohort (cohort 2, N=36) if they had a ≥ 0.5 log10 HIV-1 RNA decline compared to the screening visit or after cohort 1 reached its planned sample size.
In the 14-day functional monotherapy period, participants in cohort 1 were randomized in a 2:1 ratio in a blinded fashion to receive either SUNLENCA or placebo, while continuing their failing regimen. This period was to establish the virologic activity of SUNLENCA. After the functional monotherapy period, participants who had received SUNLENCA continued on SUNLENCA along with an OBR; participants who had received placebo during this period initiated SUNLENCA along with an OBR.
Participants in cohort 1 had a mean age of 52 years (range: 24 to 71), 72% were male, 46% were White, 46% were Black, and 9% were Asian. 29% percent of participants identified as Hispanic/Latino. The mean baseline plasma HIV-1 RNA was 4.3 log10 copies/mL (range: 2.3 to 5.4). 19% of participants had baseline viral loads greater than 100,000 copies/mL. The mean baseline CD4+ cell count was 161 cells/mm3 (range: 6 to 827). 75% of participants had CD4+ cell counts below 200 cells/mm3. The mean number of years since participants first started HIV treatment was 24 years (range: 7 to 33); the mean number of antiretroviral agents in failing regimens at baseline was 4 (range: 1 to 7). The percentage of participants in the randomized cohort with known resistance to at least 2 agents from the NRTI, NNRTI, PI and INSTI classes was 97%, 94%, 78% and 75%, respectively. In cohort 1, 53% of participants had no fully active agents, 31% had 1 fully active agent, and 17% had 2 or more fully active agents within their initial failing regimen, including 6% of participants were who were receiving fostemsavir, which was an investigational agent at the start of the CAPELLA trial.
Participants in cohort 2 initiated SUNLENCA and an OBR on Day 1.
Participants in cohort 2 had a mean age of 48 years (range: 23 to 78), 78% were male, 36% were White, 31% were Black, 33% were Asian, and 14% of participants identified as Hispanic/Latino. The mean baseline plasma HIV-1 RNA was 4.1 log10 copies/mL (range: 1.3 to 5.7). 19% of participants had baseline viral loads greater than 100,000 copies/mL. The mean baseline CD4+ cell count was 258 cells/mm3 (range: 3 to 1296). 53% of participants had CD4+ cell counts below 200 cells/mm3. The mean number of years since participants first started HIV treatment was 19 years (range: 3 to 35); the mean number of antiretroviral agents in failing regimens at baseline was 4 (range: 2 to 7). The percentage of participants in the non-randomized cohort with known resistance to at least 2 agents from the NRTI, NNRTI, PI and INSTI classes was 100%, 100%, 83% and 64%, respectively. In cohort 2, 31% of participants had no fully active agents, 42% had 1 fully active agent, and 28% had 2 or more fully active agents within their initial failing regimen, including 6% of participants who were receiving fostemsavir, which was an investigational agent at the start of the CAPELLA trial.
The primary efficacy endpoint was the proportion of participants in cohort 1 achieving ≥ 0.5 log10 copies/mL reduction from baseline in HIV-1 RNA at the end of the functional monotherapy period. The results of the primary endpoint analysis are shown in Table 13.
| SUNLENCA (N=24) | Placebo (N=12) | |
|---|---|---|
| Proportion of Participants Achieving a ≥ 0.5 log10 Decrease in Viral Load | 87.5% | 16.7% |
| Treatment Difference (95% CI) | 70.8% (34.9% to 90.0%) * | |
* p < 0.0001
The results at Weeks 26 and 52 are provided in Table 14 and Table 15.
| SUNLENCA plus OBR (N=36) | ||
|---|---|---|
| Week 26 | Week 52 | |
| OBR = optimized background regimen | ||
| HIV-1 RNA < 50 copies/mL | 81% | 83% |
| HIV-1 RNA ≥ 50 copies/mL‡ | 19% | 14% |
| No virologic data in Week 26 or 52 Window | 0 | 3% |
| Discontinued Study Drug Due to AE or Death § | 0 | 0 |
| Discontinued Study Drug Due to Other Reasons ¶ and Last Available HIV-1 RNA < 50 copies/mL | 0 | 3% |
| Missing Data During Window but on Study Drug | 0 | 0 |
* Week 26 window was between Days 184 and 232 (inclusive).
† Week 52 window was between Days 324 and 414 (inclusive).
‡ Includes participants who had ≥ 50 copies/mL in the Week 26 or 52 window; participants who discontinued early due to lack or loss of efficacy; participants who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
§ Includes participants who discontinued due to AE or death at any time point from Day 1 through the time window if this resulted in no virologic data on treatment during the specified window.
¶ Includes participants who discontinued for reasons other than an AE, death or lack or loss of efficacy, e.g., withdrew consent, loss to follow-up, etc.
| SUNLENCA plus OBR (N=36) | ||
|---|---|---|
| Week 26 | Week 52 | |
| ARV = antiretroviral; DRV=darunavir; DTG=dolutegravir; INSTI = integrase strand-transfer inhibitor; OBR = optimized background regimen; | ||
| Age (Years) | ||
| < 50 | 100% (9/9) | 89% (8/9) |
| ≥ 50 | 74% (20/27) | 81% (22/27) |
| Gender | ||
| Male | 77% (20/26) | 77% (20/26) |
| Female | 90% (9/10) | 100% (10/10) |
| Race | ||
| Black | 81% (13/16) | 75% (12/16) |
| Non-Black | 84% (16/19) | 89% (17/19) |
| Baseline plasma viral load (copies/mL) | ||
| ≤ 100,000 | 86% (25/29) | 86% (25/29) |
| > 100,000 | 57% (4/7) | 71% (5/7) |
| Baseline CD4+ (cells/mm3) | ||
| < 200 | 78% (21/27) | 78% (21/27) |
| ≥ 200 | 89% (8/9) | 100% (9/9) |
| Baseline INSTI resistance profile | ||
| With INSTI resistance | 85% (23/27) | 81% (22/27) |
| Without INSTI resistance | 63% (5/8) | 88% (7/8) |
| Number of fully active ARV agents in the OBR | ||
| 0 | 67% (4/6) | 67% (4/6) |
| 1 | 86% (12/14) | 79% (11/14) |
| ≥ 2 | 81% (13/16) | 94% (15/16) |
| Use of DTG and/or DRV in the OBR | ||
| With DTG and DRV | 83% (10/12) | 83% (10/12) |
| With DTG, without DRV | 83% (5/6) | 83% (5/6) |
| Without DTG, with DRV | 78% (7/9) | 89% (8/9) |
| Without DTG or DRV | 78% (7/9) | 78% (7/9) |
* Week 26 window was between Days 184 and 232 (inclusive).
† Week 52 window was between Days 324 and 414 (inclusive).
In cohort 1, at Weeks 26 and 52, the mean change from baseline in CD4+ cell count was 81 cells/mm3 (range: -101 to 522) and 82 cells/mm3 (range: -194 to 467), respectively.
In cohort 2, at Weeks 26 and 52, 81% (29/36) and 72% (26/36) of participants achieved HIV-1 RNA < 50 copies/mL, respectively, and the mean change from baseline in CD4+ cell count was 97 cells/mm3 (range: -103 to 459) and 113 cells/mm3 (range: -124 to 405), respectively.
Oral bridging
In CAPELLA across cohorts 1 and 2, 79% of participants (57/72) received SUNLENCA 300 mg once every 7 days as oral bridging. A total of 13, 29, and 15 participants started oral bridging following Weeks 26, 52, and 78 injections, respectively. The median (Q1, Q3) duration of oral bridging was 19 weeks (11, 22), and 12% (7/57) received oral bridging for at least 28 weeks.
In a post-hoc analysis, rates of virologic suppression and change from baseline in CD4+ cell counts in the subset of patients who received oral bridging were consistent before and during the oral bridging period.
The efficacy of SUNLENCA tablets used for oral loading as a component of the initiation regimen for BIXLENVO were evaluated in two randomized, active controlled studies in virologically suppressed adults with HIV-1, ARTISTRY-1 and ARTISTRY-2. See BIXLENVO prescribing information.
SUNLENCA tablets, 300 mg are beige, capsule-shaped, and film-coated with "GSI" debossed on one side and "62L" on the other side. SUNLENCA tablets are available in a bottle and blister packs, packaged as follows:
Bottle
Keep bottle tightly closed.
Blister Packs
Within the blister packs, tablets are packaged in a clear blister film sealed to a foil lidding material. The blister card is fitted between two paperboard cards, and packaged with silica gel desiccant in a sealed child-resistant flexible laminated pouch.
Store bottle and blister packs at 20 °C – 25 °C (68 °F – 77 °F), excursions permitted to 15 °C – 30 °C (59 °F – 86 °F) (see USP Controlled Room Temperature).
Dispense and store only in original bottle or blister pack.
SUNLENCA injection is packaged in one of two different injection kits containing the following:
Vial Access Device Injection Kit (NDC 61958-3002-1):
Withdrawal Needle Injection Kit (NDC 61958-3005-1):
The vial stoppers are not made with natural rubber latex.
Store at 20 °C to 25 °C (68 °F to 77 °F), excursions permitted between 15 °C to 30 °C (59 °F to 86 °F).
Keep the vials in the original carton until just prior to preparation of the injections in order to protect from light.
Once the solution has been drawn into the syringes, the injections should be administered as soon as possible.
Discard any unused portion of the solution.
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Drug Interactions
SUNLENCA may interact with certain drugs; therefore, advise patients to report to their healthcare provider the use of any other prescription or non-prescription medication or herbal products, including St. John's wort, during treatment with SUNLENCA [see Contraindications (4) and Drug Interactions (7)].
If SUNLENCA is discontinued, advise patients that SUNLENCA may remain in the body and affect certain other drugs for up to 9 months after receiving their last injection [see Drug Interactions (7.2, 7.3)].
Immune Reconstitution Syndrome
Advise patients to inform their healthcare provider immediately of any symptoms of infection, as in some patients with advanced HIV (AIDS), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started [see Warnings and Precautions (5.1)].
Adherence to SUNLENCA
Counsel patients about the importance of continued medication adherence and scheduled visits to maintain viral suppression and to reduce risk of loss of virologic response and development of resistance. Advise patients to contact their healthcare provider immediately if they stop taking SUNLENCA or any other drug in their antiretroviral regimen [see Dosage and Administration (2.1) and Warnings and Precautions (5.2)].
Missed Injection Dose: Treatment of HIV-1 in Heavily Treatment-Experienced Adults
Inform patients that SUNLENCA can remain in the body for up to 12 months or longer after receiving their last injection. Advise patients to contact their healthcare provider if they miss or plan to miss a scheduled injection visit and that oral SUNLENCA therapy may be used for up to 6 months to replace missed injections. Advise patients that oral dosing should be used on an interim basis only and that the maintenance injection dosage should be resumed at the earliest possible opportunity [see Dosage and Administration (2.2, 2.4) and Warnings and Precautions (5.2)].
Missed Oral Initiation Dose: Oral Loading for Initiation of BIXLENVO
Inform patients that if they miss one of the two days of oral initiation doses of SUNLENCA given with BIXLENVO to take it as soon as possible [see Dosage and Administration (2.4)].
Injection Site Reactions
Inform patients that injection site reactions (ISRs), such as swelling, pain, erythema, nodule, induration, pruritus, extravasation or mass, may occur. Nodules and indurations at the injection site may take longer to resolve than other ISRs and may be persistent. Instruct patients when to contact their healthcare provider about these reactions [see Warnings and Precautions (5.3)].
Pregnancy Registry
Inform patients that there is an antiretroviral pregnancy registry to monitor fetal outcomes of pregnant individuals exposed to SUNLENCA [see Use in Specific Populations (8.1)].
Lactation
Inform individuals with HIV-1 that the potential risks of breastfeeding include: (1) HIV-1 transmission (in infants without HIV-1), (2) developing viral resistance (in infants with HIV), and (3) adverse reactions in a breastfed infant similar to those seen in adults [see Use in Specific Populations (8.2)].
SUNLENCA and BIXLENVO are trademarks of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners.
Manufactured for and distributed by: Gilead Sciences, Inc., Foster City, CA 94404
© 2026 Gilead Sciences, Inc. All rights reserved.
| PATIENT INFORMATION | |||
|---|---|---|---|
| SUNLENCA® (sun-LEN-kuh) (lenacapavir) Tablets, for oral use | SUNLENCA® (sun-LEN-kuh) (lenacapavir) Injection, for subcutaneous use | ||
| This Patient Information has been approved by the U.S. Food and Drug Administration. | Revised: 08/2026 | ||
| What is SUNLENCA? SUNLENCA is a prescription medicine that is used with other human immunodeficiency virus-1 (HIV-1) medicines to treat HIV-1 in adults:
It is not known if SUNLENCA is safe and effective in children. | |||
| Do not receive or take SUNLENCA if you take certain other medicines called strong CYP3A inducers. Ask your healthcare provider if you are not sure. | |||
Before receiving or taking SUNLENCA, tell your healthcare provider about all your medical conditions, including if you:
Some medicines may interact with SUNLENCA. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.
| |||
| How should I receive and take SUNLENCA? If you are receive or take SUNLENCA for the treatment of HIV-1 (not for starting treatment with BIXLENVO):
| |||
| What are the possible side effects of SUNLENCA? SUNLENCA may cause serious side effects, including:
These are not all of the possible side effects of SUNLENCA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | |||
How should I store SUNLENCA?
| |||
| General information about the safe and effective use of SUNLENCA. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use SUNLENCA for a condition for which it was not prescribed. Do not give SUNLENCA to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about SUNLENCA that is written for health professionals. | |||
| What are the ingredients in SUNLENCA? Active ingredient: lenacapavir sodium Inactive ingredients: SUNLENCA tablets: copovidone, croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose, and poloxamer 407. The tablets are film-coated with a coating material containing iron oxide black, iron oxide red, iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide. SUNLENCA injection: polyethylene glycol 300 and water for injection. Manufactured for and distributed by: Gilead Sciences, Inc. Foster City, CA 94404 SUNLENCA and BIXLENVO are trademarks of Gilead Sciences, Inc., or its related companies. All other trademarks referenced herein are the property of their respective owners. © 2026 Gilead Sciences, Inc. All rights reserved. 215973-GS-007/IFU-002/IFU-WD-001/IFU-WDS-000 For more information, call 1-800-445-3235 or go to www.SUNLENCA.com. | |||
NDC 61958-3001-1
Sunlenca®
(lenacapavir) tablets
300 mg per tablet
1 pouch containing 4 tablets
Each tablet contains: 300 mg of lenacapavir
(present as 306.8 mg lenacapavir sodium).
Store at 20 °C - 25 °C (68 °F - 77 °F).
Dispense only in original container.
Recommended Dosage: See prescribing information.
KEEP OUT OF THE REACH OF CHILDREN
GILEAD
Manufactured for:
Gilead Sciences, Inc.
Foster City, CA 94404
Made in Canada
© 2022 Gilead Sciences, Inc.
NDC 61958-3001-2
Sunlenca®
(lenacapavir) tablets
300 mg per tablet
1 pouch containing 5 tablets
Each tablet contains: 300 mg of lenacapavir
(present as 306.8 mg lenacapavir sodium).
Store at 20 °C - 25 °C (68 °F - 77 °F).
Dispense only in original container.
Recommended Dosage: See prescribing information.
KEEP OUT OF THE REACH OF CHILDREN
Talk to your healthcare provider before taking
Sunlenca tablets.
Your healthcare provider will tell you when to take
Sunlenca tablets.
GILEAD
Manufactured for:
Gilead Sciences, Inc.
Foster City, CA 94404
Made in Canada
© 2022 Gilead Sciences, Inc.
NDC 61958-3001-3
4 tablets
Sunlenca®
(lenacapavir) tablets
300 mg per tablet
Talk to your healthcare provider
before taking Sunlenca tablets.
Your healthcare provider will tell you
when to take Sunlenca tablets.
Rx only
NDC 61958-3002-1
Sunlenca®
(lenacapavir) injection
463.5 mg/1.5 mL (309 mg/mL)
For Subcutaneous Injection
Contents
Both 463.5 mg/1.5 mL (2 single-dose vials) must be
administered to receive the 927 mg dose.
For Healthcare Professional administration only.
GILEAD
Rx only
NDC 61958-3005-1
Sunlenca®
(lenacapavir) injection
463.5 mg/1.5 mL (309 mg/mL)
For Subcutaneous Injection
Contents
Both 463.5 mg/1.5 mL (2 single-dose vials) must be
administered to receive the 927 mg dose.
For Healthcare Professional administration only.
GILEAD
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| a124dbe4-d4b1-4641-ba1c-c35ad0d241f9 | Product name | 1 | 20230919 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 61958-3001-1 | EA - Each | 61958-3001 | 60cee081-ef98-42a2-a077-481374399a49 | 1 | 2023-01-09 |
| 61958-3001-2 | EA - Each | 61958-3001 | 486ff8ba-9d69-4c55-9c28-ae7b8142afef | 1 | 2023-01-09 |
| 61958-3001-3 | EA - Each | 61958-3001 | ac094e0b-9f46-489c-8736-34b0c6e9e5d3 | 1 | 2025-05-14 |
| 61958-3002-1 | ML - Milliliter | 61958-3002 | 8fe90940-34a0-4a39-8d90-49d34f5d4c6d | 1 | 2023-01-09 |
| 61958-3005-1 | ML - Milliliter | 61958-3005 | 240997e1-bd23-4c9b-af65-1aa0c69dc80e | 1 | 2025-05-14 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 61958-3001 | 61958-3001-1, 61958-3001-2, 61958-3001-3 |
| 61958-3002 | 61958-3002-1 |
| 61958-3004 | 61958-3004-1 |
| 61958-3005 | 61958-3005-1 |
Every source-derived ingredient row is available through these pages.
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 13 | 2026-08-11 | daily-update | 2026-08-21 02:06:53 |
| 12 | 2026-03-12 | full-release | 2026-05-31 22:11:26 |
| 11 | 2026-02-12 | monthly-update | 2026-06-03 17:57:38 |
| 10 | 2025-10-20 | monthly-update | 2026-06-03 17:42:20 |
| 9 | 2025-09-08 | full-release | 2026-05-31 21:43:02 |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N215973-001 | SUNLENCA | LENACAPAVIR SODIUM | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 |
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N215973-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 |
| N215973-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | |
| N215973-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | |
| N215973-001 | 11267799 | 2038-08-16 | Drug substance | 2023-01-18 | |
| N215973-001 | 12594267 | 2039-07-15 | Drug product | 2026-04-21 | |
| N215973-001 | 11944611 | 2041-08-28 | U-3507 | 2024-04-23 |
| Application-product | Exclusivity code | Expiration |
|---|---|---|
| N215973-001 | NCE | 2027-12-22 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | 8072bd15b7f6… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | 3bdfa0b2c4d7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N215973-001 | SUNLENCA | EQ 463.5MG BASE/1.5ML (EQ 309MG BASE/ML) | SOLUTION / SUBCUTANEOUS | RLD, RS | 2022-12-22 | a50c72e98297… |
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N215973-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N215973-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215973-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215973-001 | 11267799 | 2038-08-16 | Drug substance | 2023-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215973-001 | 12594267 | 2039-07-15 | Drug product | 2026-04-21 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215973-001 | 11944611 | 2041-08-28 | U-3507 | 2024-04-23 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N215973-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215973-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215973-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215973-001 | 11267799 | 2038-08-16 | Drug substance | 2023-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215973-001 | 12594267 | 2039-07-15 | Drug product | 2026-04-21 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215973-001 | 11944611 | 2041-08-28 | U-3507 | 2024-04-23 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215973-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N215973-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215973-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215973-001 | 11267799 | 2038-08-16 | Drug substance | 2023-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215973-001 | 11944611 | 2041-08-28 | U-3507 | 2024-04-23 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215973-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215973-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215973-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215973-001 | 11267799 | 2038-08-16 | Drug substance | 2023-01-18 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215973-001 | 11944611 | 2041-08-28 | U-3507 | 2024-04-23 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N215973-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N215973-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N215973-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N215973-001 | 11267799 | 2038-08-16 | Drug substance | 2023-01-18 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N215973-001 | 11944611 | 2041-08-28 | U-3507 | 2024-04-23 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215973-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215973-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215973-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215973-001 | 11267799 | 2038-08-16 | Drug substance | 2023-01-18 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215973-001 | 11944611 | 2041-08-28 | U-3507 | 2024-04-23 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N215973-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N215973-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N215973-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N215973-001 | 11267799 | 2038-08-16 | Drug substance | 2023-01-18 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N215973-001 | 11944611 | 2041-08-28 | U-3507 | 2024-04-23 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N215973-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N215973-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N215973-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | 03ed91905a0d… |
| Captured | Edition | Application-product | Exclusivity code | Expiration | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N215973-001 | NCE | 2027-12-22 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N215973-001 | NCE | 2027-12-22 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N215973-001 | NCE | 2027-12-22 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215973-001 | NCE | 2027-12-22 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N215973-001 | NCE | 2027-12-22 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215973-001 | NCE | 2027-12-22 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N215973-001 | NCE | 2027-12-22 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N215973-001 | NCE | 2027-12-22 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N215973-001 | NCE | 2027-12-22 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N215973-001 | NCE | 2027-12-22 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N215973-001 | NCE | 2027-12-22 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | N215973-001 | NCE | 2027-12-22 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N215973-001 | NCE | 2027-12-22 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N215973-001 | NCE | 2027-12-22 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N215973-001 | NCE | 2027-12-22 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | N215973-001 | NCE | 2027-12-22 | 8072bd15b7f6… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N215973-001 | NCE | 2027-12-22 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | N215973-001 | NCE | 2027-12-22 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | N215973-001 | NCE | 2027-12-22 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N215973-001 | NCE | 2027-12-22 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N215973-001 | NCE | 2027-12-22 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N215973-001 | NCE | 2027-12-22 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N215973-001 | NCE | 2027-12-22 | 3f0d92c62455… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N215973-001 | NCE | 2027-12-22 | a50c72e98297… |
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N215974-001 | SUNLENCA | LENACAPAVIR SODIUM | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 |
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N215974-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 |
| N215974-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | |
| N215974-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | |
| N215974-001 | 11267799 | 2038-08-16 | Drug substance | 2023-01-18 | |
| N215974-001 | 11944611 | 2041-08-28 | U-3507 | 2024-04-23 |
| Application-product | Exclusivity code | Expiration |
|---|---|---|
| N215974-001 | NCE | 2027-12-22 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | 8072bd15b7f6… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | 3bdfa0b2c4d7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N215974-001 | SUNLENCA | EQ 300MG BASE | TABLET / ORAL | RLD, RS | 2022-12-22 | a50c72e98297… |
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N215974-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | N215974-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215974-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215974-001 | 11267799 | 2038-08-16 | Drug substance | 2023-01-18 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N215974-001 | 11944611 | 2041-08-28 | U-3507 | 2024-04-23 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N215974-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | N215974-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215974-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215974-001 | 11267799 | 2038-08-16 | Drug substance | 2023-01-18 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N215974-001 | 11944611 | 2041-08-28 | U-3507 | 2024-04-23 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215974-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | N215974-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215974-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215974-001 | 11267799 | 2038-08-16 | Drug substance | 2023-01-18 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N215974-001 | 11944611 | 2041-08-28 | U-3507 | 2024-04-23 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215974-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215974-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215974-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215974-001 | 11267799 | 2038-08-16 | Drug substance | 2023-01-18 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215974-001 | 11944611 | 2041-08-28 | U-3507 | 2024-04-23 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N215974-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | N215974-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N215974-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N215974-001 | 11267799 | 2038-08-16 | Drug substance | 2023-01-18 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N215974-001 | 11944611 | 2041-08-28 | U-3507 | 2024-04-23 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215974-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215974-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215974-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215974-001 | 11267799 | 2038-08-16 | Drug substance | 2023-01-18 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215974-001 | 11944611 | 2041-08-28 | U-3507 | 2024-04-23 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N215974-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N215974-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N215974-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N215974-001 | 11267799 | 2038-08-16 | Drug substance | 2023-01-18 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N215974-001 | 11944611 | 2041-08-28 | U-3507 | 2024-04-23 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N215974-001 | 9951043 | 2034-02-28 | U-3507 | Drug substance, Drug product | 2023-01-18 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N215974-001 | 10071985 | 2037-08-17 | Drug substance, Drug product | 2023-01-18 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N215974-001 | 10654827 | 2037-08-17 | U-3507 | 2023-01-18 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N215974-001 | 11267799 | 2038-08-16 | Drug substance | 2023-01-18 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N215974-001 | 11944611 | 2041-08-28 | U-3507 | 2024-04-23 | 03ed91905a0d… |
| Captured | Edition | Application-product | Exclusivity code | Expiration | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N215974-001 | NCE | 2027-12-22 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N215974-001 | NCE | 2027-12-22 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N215974-001 | NCE | 2027-12-22 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N215974-001 | NCE | 2027-12-22 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N215974-001 | NCE | 2027-12-22 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N215974-001 | NCE | 2027-12-22 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N215974-001 | NCE | 2027-12-22 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N215974-001 | NCE | 2027-12-22 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N215974-001 | NCE | 2027-12-22 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N215974-001 | NCE | 2027-12-22 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N215974-001 | NCE | 2027-12-22 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | N215974-001 | NCE | 2027-12-22 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N215974-001 | NCE | 2027-12-22 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N215974-001 | NCE | 2027-12-22 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N215974-001 | NCE | 2027-12-22 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | N215974-001 | NCE | 2027-12-22 | 8072bd15b7f6… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N215974-001 | NCE | 2027-12-22 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | N215974-001 | NCE | 2027-12-22 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | N215974-001 | NCE | 2027-12-22 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N215974-001 | NCE | 2027-12-22 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N215974-001 | NCE | 2027-12-22 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N215974-001 | NCE | 2027-12-22 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N215974-001 | NCE | 2027-12-22 | 3f0d92c62455… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | N215974-001 | NCE | 2027-12-22 | a50c72e98297… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Sunlenca | LENACAPAVIR SODIUM | Gilead Sciences, Inc. | e5652804-29c4-40d7-aeb2-0142ed2a7b5b | 2026-08-27 | Warnings, Adverse reactions | 61958-3005-1 61958-3001-3 61958-3004-1 61958-3001-2 61958-3001-1 61958-3002-1 61958-3005 61958-3001 61958-3002 61958300401 61958300101 61958300201 61958300501 61958300102 61958300103 142b440e-6eae-4d76-8312-b094de1380c3 e5652804-29c4-40d7-aeb2-0142ed2a7b5b |
Adverse event summaries are temporarily unavailable. Other product information remains available.